STUDY DESIGN AND METHODS:
We proposed to gain insight into hematologists' beliefs about antithrombotic prescription in hematologic malignancy patients, to design future clinical trials. Therefore, we conducted a survey in France to evaluate the practices among a panel of hematologists.
RESULTS:
We found that more than 92% of the respondents prescribed therapeutic anticoagulation in case of pulmonary embolism or deep venous thrombosis. In the case of therapeutic anticoagulation, only 64% of the physicians reconsidered treatment under a platelet threshold of 50 3 10 9 /L. None of the respondents decided to renounce treatment, nor to discontinue it because of thrombocytopenia, except in distal venous thrombosis or superficial vein thrombosis. One-fifth of clinicians proposed the insertion of a vena cava filter.
CONCLUSION: As observed in the United States and
Canada, we noticed discrepancies between recommendations and current practices in France. This highlights the urgent need to conduct studies to evaluate both efficacy and safety of antithrombotics in patients with hematologic cancer and thrombocytopenia. P atients with hematologic malignancies are at high risk for both thrombosis and hemorrhage. Indeed, epidemiologic studies suggest that the rate of venous thromboembolism (VTE) in such patients is high despite thrombocytopenia and clearly impacts the patients' prognosis. 1, 2 Even if the rate of arterial thrombosis seems to be lower, no epidemiologic studies previously addressed this question. VTE, including pulmonary embolism (PE), deep venous thrombosis (DVT), and catheter-related thrombosis occurred in 5.2% of acute myeloid leukemia patients over a 2-year period, in 5% of multiple myeloma patients, in 4.5% of acute lymphoid leukemia patients, and in 4.5% of non-Hodgkin's lymphoma patients. 3 Other published studies reported higher rates: for example, in multiple myeloma patients, the reported incidence of VTE ranged from 0% to 35% in a Furthermore some patients may receive anticoagulant therapy due to their medical history such as, for example, atrial fibrillation or prosthetic heart valve. Finally, the patients with hematologic malignancies receiving anticoagulant therapy either for a new thrombotic event or due to their past medical history represent a relatively common situation.
Patients were treated with full-dose anticoagulation whatever the type of the thrombosis (PE, distal DVT [DDVT], proximal DVT [PDVT], and catheter-related thrombosis). Similar observations have been made in some case series. 7, 8 Additionally, heparin was widely used as the first choice for anticoagulation treatment, and VTE treatment, in cancer patients. 9 This agent appears to be preferred to vitamin K antagonist (VKA) or new direct oral anticoagulants, according to a study showing that lowmolecular-weight heparin (LMWH) was associated with lower rates of VTE recurrence, compared to VKA. Moreover, unfractionated heparin may be preferred for the initial treatment of VTE in case of high risk of bleeding, because of its prompt elimination when used intravenously (IV). Over the past decade, several large randomized controlled trials have been published that address important questions about platelet (PLT) transfusions and treatment of hematologic malignancies. These trials did not include patients treated with antithrombotics. In addition, the PLT transfusion trials suggested that bleeding risk does not depend on a PLT threshold when higher than 10 3 10 9 /L compared with the higher thresholds. [10] [11] [12] The incidence of major bleeding as a complication of anticoagulation therapy in patients with thrombocytopenia is unknown. In patients with thrombocytopenia without anticoagulation, this incidence is approximately 5% (World Health Organization Grade 4).
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The International Society of Thrombosis and Hemostasis (ISTH) and the American Society of Clinical Oncology edited guidelines concerning the management of patients with cancer-associated thrombosis. They recommend a "safe" use of anticoagulation therapy, that is, only in patients with a PLT count above an empiric threshold of 50 310 9 /L. PLT transfusions are also recommended by the ISTH with the goal of maintaining a PLT count higher than this threshold of 50 3 10 9 /L if a therapeutic anticoagulation is warranted. 13 Finally, whether input from literature or guidelines led to antithrombotic prescription in hematologic malignancies remains unknown. Important questions were unanswered, especially regarding both indications and PLT threshold for transfusion. Therefore, it appears of a great importance to gain insight into hematologists' beliefs about antithrombotic prescription, both for the design of clinical trials and for medicoeconomic analyses. As a result, we decided to conduct a survey in France, to evaluate the practices and beliefs among a panel of hematologists, regarding the management of antithrombotic treatments in patients with hematologic malignancies.
MATERIALS AND METHODS
The study was designed as an electronic survey addressed to hematologists. In March and May 2015, an electronic questionnaire was sent to the members of both the French Society of Hematology (Soci et e Française d'H ematologie) and the Hemostasis and Thrombosis study group (Groupe Français d' Etudes sur l'H emostase et la Thrombose), jointly with the society's monthly review. The members were asked to respond to the survey by clicking on a link that would be open until June 2015. The survey included 46 questions (Appendix S1, available as supporting information in the online version of this paper), most of them multiple choice, including six questions regarding the characteristics of both the responders and their wards. Questions 7 to 10 referred to PLT thresholds. Physicians were especially asked to specify a precise PLT count above which they would feel it necessary to prescribe a therapeutic or prophylactic anticoagulation and an anti-PLT therapy. Questions 11 to 40 referred to the management approach in different case scenarios (PE, DVT, catheterrelated thrombosis, etc.). Questions 41 to 46 referred to alternative therapeutics for thrombosis and bleeding event (cava filter, tranexamic acid).
Statistical analysis
The results are reported as numbers and percentages.
RESULTS

Respondents' characteristics
Of the 98 physicians who responded to the questionnaire, 95 were from France, working across 33 different counties, representing 19 of the 30 French academic centers. Among the French physicians, 47 respondents (49.4%) were attending physicians and 43 were physicians with academic activities (45.3%) including 20 heads of wards (21.1%; Table 1 ). Eighty-four physicians (88.4%) worked in a university-affiliated hospital or in a cancer center. The respondents were 71 clinical hematologists (74.7%), 10 biologic hematologists (with only laboratory activities; 10.5%), and five oncologists (5.3%). Eighty-four respondents reported treating daily or weekly patients with PLT count of less than 50 3 10 9 /L (88.4%), seven monthly, and four less than once per month. The main characteristics of the respondents and their wards are shown in Table 1 .
PLT threshold
Ninety-two percent of the respondents paid attention to the PLT count when they prescribed an antithrombotic therapy in patients with hematologic malignancies undergoing intensive chemotherapy inducing severe thrombocytopenia. In case of therapeutic anticoagulation, 5% of the physicians (n 5 5) reported reassessing benefits and /L, and 6% (n 5 6) a threshold of 10 3 10 9 /L, whereas the PLT count did not influence the decision of anticoagulation for 12.6% (n 5 12). Finally, in case of anti-PLT therapy, 66% (n 5 63) of the physicians considered a threshold of 50 3 10 9 or 30 3 10 9 /L to reassess benefits and risks of this treatment (Fig. 1) .
Clinical scenario PE
We asked the physicians to report their management approach in a clinical scenario of PE in a patient with significant thrombocytopenia after intensive chemotherapy (i.e., acute leukemia induction therapy, autologous or allogeneic stem cell transplantation). "Significant" means a subjective PLT count threshold, chosen by the physicians, below which they reassess the standard attitude. Nearly every respondent (n 5 90, 94.7%) reported to prescribe a therapeutic anticoagulation in PE with significant thrombocytopenia, as well in the case of new diagnosis as recent diagnosis requiring therapeutic anticoagulation in a standard situation; among these physicians, 73 (76.7%) associated PLT transfusions with the anticoagulation. Only 3% of the responders (n 5 3) chose a prophylactic anticoagulation that they did not associate with PLT transfusions. None of the responders stopped the anticoagulation nor refrained from treatment due to significant thrombocytopenia.
The most commonly used anticoagulation treatment is heparin: LMWH (n 5 55/93, 59%) and unfractionated heparin (n 5 35, 37.6%), mostly IV. Among the physicians who prescribed PLT transfusions associated with anticoagulation, 81% (n 5 59) felt comfortable with a threshold of 50 3 10 9 /L, and 16% (n 5 12) with a threshold of 30 3 10 9 /L ( Table 2 ). 
DVT
Proximal. The huge majority of the respondents (92%, n 5 88) reported prescribing a therapeutic anticoagulation in PDVT patients with significant thrombocytopenia. Among these physicians, 77% (n 5 68) associated a PLT transfusion therapy with the anticoagulation. Only 4% of the responders chose to prescribe a prophylactic anticoagulation without PLT transfusion. None of the respondents decided not to treat patients nor to discontinue the treatment because of thrombocytopenia. Regarding the treatment modalities, 62% (n 5 57) of the respondents reported using preferentially LMWH and 33% (n 5 30) using unfractionated heparin. Regarding PLT transfusions, 82% (n 5 56) of the physicians used a PLT threshold of 50 3 10 9 /L, and 16% (n 5 11) a threshold of 30 3 10 9 /L (Table 2 ). In case of PDVT in a context of thrombocytopenia, 7% (n 5 7) of the physicians recommended the placement of a vena cava filter systematically, 12% (n 5 11) often recommended its placement, 18% (n 5 17) occasionally, 41% (n 5 39) rarely, and 22% (n 5 21) never recommended it.
Distal. For DDVT, the treatment widely differed across respondents. Twenty-five percent (n 5 23) of the respondents reported not prescribing any anticoagulation therapy. Among the respondents, 70% (n 5 66) reported prescribing a therapeutic anticoagulation and in association with PLT transfusion for 57% (n 5 54) of them. Regarding PLT transfusions, 83% (n 5 45) of the physicians used a PLT threshold of 50 3 10 9 /L, and 15% (n 5 8) a threshold of 30 3 10 9 /L (Table 2) .
Central venous catheter thrombosis
In the case of catheter-related thrombosis in a patient experiencing intensive chemotherapy inducing severe thrombocytopenia, 85% of the respondents reported prescribing therapeutic anticoagulation. Among these respondents, 62% (n 5 59) reported associating PLT transfusion with the anticoagulation treatment. Regarding PLT transfusions, 80% (n 5 47) of the physicians used a PLT threshold of 50 3 10 9 /L, and 17% (n 5 10) a threshold of 30 3 10 9 /L (Table 2) . Moreover, 34% (n 5 32) of the physicians recommended removal of the catheter whereas 66% (n 5 63) did not recommend it. Among the respondents who removed the catheter, 22% (n 5 7) removed it immediately, 25% (n 5 8) after at least 48 hours of effective anticoagulation, and 9% (n 5 3) after 1 week of effective anticoagulation; in 16% (n 5 5) the timing of removal was not provided. 
Superficial vein thrombosis
Regarding patients with superficial vein thrombosis, most of the respondents (56.8%, n 5 54) reported not using any anticoagulation therapy, and 37% (n 5 35) reported prescribing prophylactic anticoagulation, including four physicians using PLT transfusions associated with their treatment. Surprisingly, 3% (n 5 3) reported recommending a therapeutic anticoagulation; LMWH was the most prescribed (68.4%, n 5 26; Table 2 ).
Mechanical heart valve
Concerning mechanical heart valves, the vast majority of the physicians (85.3%, n 5 81) reported prescribing therapeutic anticoagulation. They often associated this treatment with PLT transfusions (63.1%, n 5 60) to maintain a PLT count higher than 50 3 10 9 /L (81.7%, n 5 49) or 30 3 10 9 /L (15%, n 5 9). As for the treatment, unfractionated heparin (41.3%, n 5 38), LMWH (34.8%, n 5 32), and VKA (18.5%, n 5 17) were prescribed ( Table 2) .
Atrial fibrillation
In patients with a theoretical indication for full-dose anticoagulation, most of the physicians (61.1%, n 5 58) chose to give a therapeutic dose of anticoagulation, including 44.2% (n 5 42) with PLT transfusion support, aiming at a 50 3 10 9 /L PLT threshold (81%, n 5 34). It is interesting to note that only 13.7% (n 5 13) of the respondents chose a prophylactic dose of anticoagulation, and 6.3% (n 5 8), only anti-PLT drugs (Table 2 ).
DISCUSSION
We found that therapeutic anticoagulant treatment associated with PLT transfusion to maintain a PLT threshold of higher than 50 310 9 /L is considered as the better option for most physicians in France, to treat PE, PDVT, central venous catheter thrombosis, and mechanical heart valve. This PLT count cutoff of 50 3 10 9 /L is proposed by international guidelines but is based on exclusion criteria used in clinical trials rather than evidence based. None of the responders stopped the anticoagulation nor refrained from treatment in case of significant thrombocytopenia, except in distal venous thrombosis or superficial vein thrombosis. A lower PLT threshold (30 310 9 /L) for PLT transfusion is used by nearly 15% of responders in most clinical scenarios. Other treatment options, such as prophylactic anticoagulant therapy or vena cava filter, are rarely reported. All these choices appear to be consensual in France as the responders represent more than 60% of the 30 academic centers. Moreover, they reflect the current practices as 90% of the respondents reported treating daily or weekly patients with PLT counts of less than 50 3 10 9 /L. Different treatment attitudes have been recently reported in a survey conducted in 19 different academic centers across the United States and Canada.
14 Indeed, when faced with a patient with a PE, 4 days after allogeneic HSCT for myelofibrosis and with a PLT count of 10 310 9 /L, almost 30% of North American physicians placed a vena cava filter and postponed anticoagulation treatment until spontaneous PLT count recovery, and 53% of physicians started therapeutic anticoagulation and transfused to maintain a PLT count of higher than 50 310 9 /L versus 63% of French physicians. Additionally, when faced with a patient with a catheter-associated thrombosis, only 30% of North American responders started full anticoagulation and maintained the PLT count of higher than 50 310 9 /L versus 50% of French physicians. Several reasons may explain the different results between the American survey and ours. One of them is the low number of hematologists who specialized in hematologic malignancies (n 5 10), among the 30 physicians interviewed in the American survey, compared to 71 among 95 physicians in our study. Another explanation for this difference is that PLT transfusions are not recommended by the American Society of Clinical Oncology, whereas they are by the ISTH. Moreover, a prophylactic dose of anticoagulation was chosen by many American physicians when the PLT count was low (20 3 10 9 /L) whereas this option was anecdotal in France. To the best of our knowledge the use of prophylactic doses of heparin in patients with thrombocytopenia has never been evaluated in randomized studies. Therefore, no study ever reported patients with hematologic malignancies experiencing thrombocytopenia and not being treated in case of VTE. Our findings demonstrate that the current international guidelines are not well applied. Indeed, if there is a consensus to propose a therapeutic dose of heparin in patients with a PLT count of higher than 50 310 9 /L, 20% of French clinicians used a lower threshold of PLT (30 3 10 9 /L), 20% suggested the insertion of a vena cava filter, and less than 5% considered either a prophylactic dose of heparin or discontinuation of anticoagulants. In the literature, concerning the choice of a PLT count threshold, we noticed that a 20 3 10 9 /L cutoff is sometimes used in reported cases. 8 In a few cases in our study, anticoagulation was decided after taking advice from an external therapeutic team. The hematologists usually chose to use heparin, due to their limited experience with new treatments. The safety and efficacy data from previous trials suggest that heparin is an acceptable treatment, but long-term followup is required to validate these data, especially as the bleeding risk is important. Prandoni 6 showed that thrombosis recurrence, as well as increased incidence of bleeding events, were both related to cancer. In his study, the 12-month cumulative incidence of major bleeding was 12.4% (95% CI, 6.5%-18.2%) in patients with cancer (when patients did not have thrombocytopenia, defined as < 50 3 10 9 /L) and 4.9% (95% CI, 2.5%-7.4%) in patients without cancer. In the case series by Lim and Enjeti, 8 among five cases, two major bleedings (intracranial and gastrointestinal) were reported, among which one was fatal and one was minor. The two patients with major bleedings had the lowest PLT count (22 3 10 9 and 30 3 10 9 /L). Our study showed that hematologists paid close attention to the PLT count especially when prescribing anticoagulation or anti-PLT therapy, because of the potential bleeding risk. However, whereas in patients without anticoagulation a higher risk of bleeding is widely admitted when PLT count is less than 10 3 10 9 /L, 11,12 such a precise threshold has not yet been established in patients receiving anticoagulants. We also gained insight into anti-PLT treatment. Interestingly, our respondents also reported using a PLT threshold when prescribing anti-PLT treatment. To our knowledge, our study is the only one to address this question. In a few cases of our study, this prescription was managed by the cardiology or the therapeutic team. Two-thirds of the respondents considered a PLT threshold between 50 3 10 9 and 30 3 10 9 /L, whereas the French drug safety agency suggests a 20 3 10 9 /L PLT threshold; 15 however, this threshold is only based on an expert opinion. Current literature suffers from a lack of assessment of major bleeding and thrombosis rates, in frequent clinical scenarios. We are presently conducting a prospective register in France, including patients with hematologic cancers who are at need for therapeutic doses of anticoagulant, with the goal to reach a sample size allowing pertinent epidemiologic and clinical research. Our study has several limitations. First, the number of respondents represents only 60% of the practitioners of the 30 French academic centers. Second, a selection bias was undoubtedly present, as physicians who have a special interest in the anticoagulation of patients with thrombocytopenia were far more likely to respond. Finally, we reported the beliefs of hematology clinicians rather than their actual practices. Therefore, the reported responses may reflect the politically desirable answer rather than the respondents' actual beliefs.
In conclusion, the use of antithrombotic treatments is challenging, as patients with hematologic malignancies undergoing intensive chemotherapy inducing severe thrombocytopenia are at risk of both thrombosis and bleeding. Recommendations exist but the level of justification of these recommendations is low. First, there is a large lack of published data. Second, these guidelines are rather general, while each individual decision of treatment requires to take into account the type of thrombosis, its localization, patients' comorbidities, recent episodes of bleeding, and so forth. One striking finding of this study is that the hematologists have considerable preference for active treatment with full-dose anticoagulation and PLT transfusions. Despite the fact that PLT count per se has never been shown to correlate with bleeding in patients with thrombocytopenia, hematologists pay the greatest attention to PLT count when anticoagulation or anti-PLT therapy are needed. The current decision of antithrombotic prescription in a patient suffering from thrombocytopenia is left to the prescriber's discretion, who must weigh pros and cons in each individual case. In light of the current paucity of evidence to guide management of these patients, our findings support the need for prospective trials to better define the risks and benefits of different management strategies for antithrombotic therapy and PLT transfusions in hematological malignancy patients presenting chemotherapy-induced thrombocytopenia.
